Prodotto aggiunto correttamente al carrello.

discount label
H-EGSRNQDWL-OH
Visualizzare in 3D

Biosynth logo

H-EGSRNQDWL-OH

Rif. 3D-PP45590

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-EGSRNQDWL-OH
Sinonimi:
  • NH2-Glu-Gly-Ser-Arg-Asn-Gln-Asp-Trp-Leu-OH
Descrizione:

Peptide H-EGSRNQDWL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-EGSRNQDWL-OH include the following: gp100/pmel 17 is a murine tumor rejection antigen: induction of"self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk , A Tsung, KR Irvine - The Journal of , 1998 - rupress.orghttps://rupress.org/jem/article-abstract/188/2/277/7712 gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of"Self"-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand W Willem, MR Parkhurst, TJ Goletz, K Tsung - The Journal of , 1998 - academia.eduhttps://www.academia.edu/download/41984571/gp100pmel_17_Is_a_Murine_Tumor_Rejection20160203-5394-1pkofkb.pdf Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity UM Abdel-Motal, K Wigglesworth, U Galili - Cancer Immunology , 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-009-0662-2 Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself TR Schlingmann, FH Rininsland, WC Bartholomae - Clinical , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521661609007001 Antitumor peptide-based vaccine in the limelight T Kumai, H Yamaki, M Kono, R Hayashi, R Wakisaka - Vaccines, 2022 - mdpi.comhttps://www.mdpi.com/2076-393X/10/1/70 T cells modified with CD70 as an alternative cellular vaccine for antitumor immunity SE Lee, AR Shin, HJ Sohn, HI Cho - Cancer Research and , 2020 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373873/ CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular PD Gregor, JD Wolchok, CR Ferrone , H Buchinshky - Vaccine, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X04000933 Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses N Cousin, S Cap, M Dihr, C Tacconi , M Detmar - Cancer Research, 2021 - AACRhttps://aacrjournals.org/cancerres/article-abstract/81/15/4133/670246 Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax® M Mansour, B Pohajdak, WM Kast - Journal of Translational , 2007 - Springerhttps://link.springer.com/article/10.1186/1479-5876-5-20 The good, the bad and the ugly: how altered peptide ligands modulate immunity M Katsara, G Minigo , M Plebanski - Expert opinion on , 2008 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14712590802494501 Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2 M Derouazi, Y Wang, R Marlu, O Epaulard - Bioengineered , 2010 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/bbug.1.1.9482 Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma LV Ly, M Sluijter, SH van der Burg - The Journal of , 2013 - journals.aai.orghttps://journals.aai.org/jimmunol/article/190/1/489/86499 Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm LV Ly, M Sluijter, M Versluis, GPM Luyten - Cancer research, 2010 - AACRhttps://aacrjournals.org/cancerres/article-abstract/70/21/8339/560991 The MHC class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer I Hafstrand, EM Doorduijn, AD Duru - The Journal of , 2016 - journals.aai.orghttps://journals.aai.org/jimmunol/article/196/5/2327/102372 Going Pro to enhance T-cell immunogenicity: E asy as Ï€? HD Hickman , JW Yewdell - European journal of immunology, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201344095 Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles H Yan, G Lin, Z Liu, F Gu, Y Zhang - Acta Biomaterialia, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1742706123001204 Molecular basis for enhanced T-cell recognition and cross-reactivity E Allerbring - 2014 - search.proquest.comhttps://search.proquest.com/openview/db5cc2850745b4dfd296792c34c09473/1?pq-origsite=gscholar&cbl=2026366&diss=y Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin D Sancho , D Mouraca£o-Sa , OP Joffre - The Journal of , 2008 - Am Soc Clin Investighttps://www.jci.org/articles/view/34584 olecular basis for enhanced T-cell recognition and cross-reactivity A Eva - academia.eduhttps://www.academia.edu/download/71465254/Thesis_Eva_Allerbring.pdf

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP45590 H-EGSRNQDWL-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".